Your browser doesn't support javascript.
loading
Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria.
Tian, Ya; Zheng, Zhongyuan; Wang, Xi; Liu, Shuzhi; Gu, Liwei; Mu, Jing; Zheng, Xiaojun; Li, Yujie; Shen, Shuo.
Afiliación
  • Tian Y; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China.
  • Zheng Z; The Hospital of Nanbu County, Sichuan, People's Republic of China.
  • Wang X; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China.
  • Liu S; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China.
  • Gu L; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China.
  • Mu J; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China.
  • Zheng X; Chinese Traditional Medicine Resource Center, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China.
  • Li Y; Pharmacy Department of the first hospital of Shanxi Medical University, Shanxi, 10114, People's Republic of China.
  • Shen S; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China. yjli@icmm.ac.cn.
J Nanobiotechnology ; 20(1): 318, 2022 Jul 06.
Article en En | MEDLINE | ID: mdl-35794597
Cerebral malaria (CM) is a life-threatening neurological complication caused by Plasmodium falciparum. About 627,000 patients died of malaria in 2020. Currently, artemisinin and its derivatives are the front-line drugs used for the treatment of cerebral malaria. However, they cannot target the brain, which decreases their effectiveness. Therefore, increasing their ability to target the brain by the nano-delivery system with brain-targeted materials is of great significance for enhancing the effects of antimalarials and reducing CM mortality. This study used glucose transporter 1 (GLUT1) on the blood-brain barrier as a target for a synthesized cholesterol-undecanoic acid-glucose conjugate. The molecular dynamics simulation found that the structural fragment of glucose in the conjugate faced the outside the phospholipid bilayers, which was conducive to the recognition of brain-targeted liposomes by GLUT1. The fluorescence intensity of the brain-targeted liposomes (na-ATS/TMP@lipoBX) in the mouse brain was significantly higher than that of the non-targeted liposomes (na-ATS/TMP@lipo) in vivo (P < 0.001) after intranasal administration. The infection and recurrence rate of the mice receiving na-ATS/TMP@lipoBX treatment were significantly decreased, which had more advantages than those of other administration groups. The analysis of pharmacokinetic data showed that na-ATS/TMP@lipoBX could enter the brain in both systemic circulation and nasal-brain pathway to treat malaria. Taken together, these results in this study provide a new approach to the treatment of cerebral malaria.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Malaria Cerebral / Nanocompuestos Límite: Animals Idioma: En Revista: J Nanobiotechnology Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Malaria Cerebral / Nanocompuestos Límite: Animals Idioma: En Revista: J Nanobiotechnology Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido